Characterization and Analysis of Biopharmaceutical Proteins

Separation Science and Technology

Volumn 10, Issue C, 2011, Pages 283-359

  Luo, Yin ^a   Matejic, Tatjana ^a   Ng, Chee Keng ^a   Nunnally, Brian ^a   Porter, Thomas ^a   Raso, Stephen ^a   Rouse, Jason ^a   Shang, Tanya ^a   Steckert, John ^a  

^a PFIZER INC   (United States)

Author keywords

Bioanalytical methods; Biopharmaceutical analysis; Protein therapeutics; Structure and function

Indexed keywords

EID: 78649926584     PISSN: 18771718     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-375680-0.00008-5     Document Type: Book

References (216)

1. http://www.pharmamanufacturing.com/articles/2009/058.html?page=full.
2. Jensen O.N. Modification-specific proteomics: Characterization of post-translational modifications by mass spectrometry. Curr. Opin. Chem. Biol. 2004, 8:33-41.
3. ICH Harmonised Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products Q6b.
4. Rathore A.S. Roadmap for implementation of quality by design (QbD) for biotechnology products. Cell 2009, 27:546-553.
5. Judd R.C. Peptide Mapping by High-Performance Liquid Chromatography 2002, Protein Protocols Handbook. 2nd ed.
6. US Pharmacopeia 1055 Biotechnology-Derived Articles-Peptide Mapping 2009.
7. Mann M., Højrup P., Roepstorff P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol. Mass Spectrom. 1994, 22:338-345.
8. Blackburn R.K., Moseley M.A. Quadrupole time-of-flight mass spectrometry: A powerful new tool for protein identification and characterization. Am. Pharm. Rev. 1999, 2:49-59.
9. Morris H.R., Paxton T., Dell A., Langhorne J., Berg M., Bordoli R.S., Hoyes J., Bateman R.H. High sensitivity collisionally-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 1996, 10:889-896.
10. Charles L. Flow injection of the lock mass standard for accurate mass measurement in electrospray ionization time-of-flight mass spectrometry coupled with liquid chromatography. Rapid Commun. Mass Spectrom. 2003, 17:1383-1388.
11. Rouse J.C., McClellan J.E., Patel H.K., Jankowski M.A., Porter T.J. Top-down characterization of protein pharmaceuticals by liquid chromatography/mass spectrometry application to recombinant Factor IX comparability-A case study. Methods Mol. Biol. 2005, 308:435-460.
12. Johnson K.A., Paisley-Flango K., Tangarone B.S., Porter T.J., Rouse J.C. Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain. Anal. Biochem. 2007, 360:75-83.
13. Porter T.J., Rathore S., Rouse J.C., Denton M. Biomolecules in tissue engineered medical products (TEMPs): A case study of recombinant human bone morphogenetic protein-2 (rhBMP-2). Tissue Eng. Med. Prod. 2004, 1:150-171.
14. Geromanos S.J., Vissers J.P.C., Silva J.C., Dorschel C.A., Li G.-Z., Gorenstein M.V., Bateman R.H., Langridge J.I. The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS/MS. Proteomics 2009, 9:1683-1695.
15. Li G.-Z., Vissers J.P.C., Silva J.C., Golick D., Gorenstein M.V., Geromanos S.J. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 2009, 9:1696-1719.
16. Olsen J.V., de Godoy L.M.F., Li G., Macek B., Mortensen P., Pesch R., Makarov A., Lange O., Horning S., Mann M. Parts per million mass accuracy on an orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 2005, 4:2010-2021.
17. Haas W., Faherty B.K., Gerber S.A., Elias J.E., Beausoleil S.A., Bakalarski C.E., Li X., Villen J., Gygi S.P. Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol. Cell. Proteomics 2006, 5:1326-1337.
18. Yates J.R., Cociorva D., Liao L., Zabrouskov V. Performance of a linear ion trap-orbitrap hybrid for peptide analysis. Anal. Chem. 2006, 78:493-500.
19. Asa D. High performance mass spectrometry for small molecule and protein applications. Curr. Trends Mass Spectrom. 2009, 30-32. (supplement to spectroscopy).
20. Xie H., Gilar M., Gebler J.C. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. Anal. Chem. 2009, 81:5699-5708.
21. Edman P. Sequence determination. Mol. Biol. Biochem. Biophys. 1970, 8:211-255.
22. Heinrikson R.L. Application of automated sequence analysis to the understanding of protein structure and function. Ann. Clin. Lab. Sci. 1978, 8:295-301.
23. Mozdzanowski J. Deblocking of proteins containing N-terminal pyroglutamic acid. Methods Mol. Biol. 2003, 211:365-369.
24. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82:70-77.
25. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. 1968, 25:192-205.
26. Habeeb A.F.S.A. Reaction of protein sulfhydryl groups with Ellman's reagent. Methods Enzymol. 1972, 25:457-464.
27. Bulaj G., Kortemme T., Goldenberg D.P. Ionization-reactivity relationships for cysteine thiols in polypeptides. Biochemistry 1998, 37:8965-8972.
28. Riddles P.W., Blakeley R.L., Zerner B. Ellman's reagent: 5, 5'-dithiobis(2-nitrobenzoic acid)-A reexamination. Anal. Biochem. 1978, 94:75-81.
29. Riddles P.W., Blakeley R.L., Zerner B. Reassessment of Ellman's reagent. Methods Enzymol. 1983, 91:49-60.
30. Hatsuo M., Matsuno H., Ushida M., Katayama K., Saeki K., Itoh N. 2, 4-Dinitrobenzenesulfonyl fluoresceins as fluorescent alternatives to Ellman's reagent in thiol-quantification enzyme assays. Angew. Chem. Int. Ed. 2005, 44:2922-2925.
31. Pullela P.K., Chiku T., Carvan M.J., Sem D.S. Fluorescence-based detection of thiols in vitro and in vivo using dithiol probes. Anal. Biochem. 2006, 352:265-273.
32. Hansen R.E., Ostergaard H., Norgaard P., Winther J.R. Quantification of protein thiols and dithiols in the picomolar range using sodium borohydride and 4, 4'-dithiodipyridine. Anal. Biochem. 2007, 363:77-82.
33. Wright S.K., Viola R.E. Evaluation of methods for the quantitation of cysteines in proteins. Anal. Biochem. 1998, 265:8-14.
34. Yi L., Li H., Sun L., Liu L., Zhang C., Xi Z. A highly sensitive fluorescence probe for fast thiol-quantification assay of glutathione reductase. Angew. Chem. Int. Ed. 2009, 48:4034-4037.
35. Mhatre R., Woodard J., Zeng C. Strategies for locating disulfide bonds in a monoclonal antibody via mass spectrometry. Rapid Commun. Mass Spectrom. 1999, 13:2503-2510.
36. Mikesh L.M., Ueberheide B., Chi A., Coon J.J., Syka J.E.P., Shabanowitz J., Hunt D.F. The utility of ETD mass spectrometry in proteomic analysis. Biochim. Biophys. Acta 2006, 1764:1811-1822.
37. Wu S.-L., Jiang H., Lu Q., Dai S., Hancock W.S., Karger B.L. Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation. Anal. Chem. 2009, 81:112-122.
38. Qi J., Wu J., Somkuti G.A., Watson J.T. Determination of the disulfide structure of sillucin, a highly knotted, cysteine-rich peptide, by cyanylation/cleavage mass mapping. Biochemistry 2001, 40:4531-4538.
39. Zhang W., Marzilli L.A., Rouse J.C., Czupryn M.J. Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody. Anal. Biochem. 2002, 311:1-9.
40. Chelius D., Wimer M.E.H., Bondarenko P.V. Reversed-phase liquid chromatography in-line with negative ionization electrospray mass spectrometry for the characterization of the disulfide-linkages of an immunoglobulin gamma antibody. J. Am. Soc. Mass Spectrom. 2006, 17:1590-1598.
41. Wypych J., Li M., Guo A., Zhang Z., Martinez T., Allen M.J., Fodor S., Kelner D.N., Flynn G.C., Liu Y.D., et al. Human IgG2 antibodies display disulfide-mediated structural isoforms. J. Biol. Chem. 2008, 283:16194-16205.
42. Zhao L., Almaraz R.T., Xiang F., Hedrick J.L., Franza A.H. Gas-phase scrambling of disulfide bonds during matrix-assisted laser desorption/ionization mass spectrometry analysis. J. Am. Soc. Mass Spectrom. 2009, 20:1603-1616.
43. Zhang B., Cockrill S.L. Methodology for determining disulfide linkage patterns of closely spaced cysteine residues. Anal. Chem. 2009, 81:7314-7320.
44. Canova-Davis E., Baldonado I.P., Chloupek R.C., Ling V.T., Gehant R., Olson K., Gillece-Castro B.L. Confirmation by mass spectrometry of a trisulfide variant in methionyl human growth hormone biosynthesized in Escherichia coli. Anal. Chem. 1996, 68:4044-4051.
45. Pristatsky P., Cohen S.L., Krantz D., Acevedo J., Ionescu R., Vlasak J. Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody. Anal. Chem. 2009, 81:6148-6155.
46. Gu S., Wen D., Weinreb P.H., Sun Y., Zhang L., Foley S.F., Kshirsagar R., Evans D., Mi S., Meier W., et al. Characterization of trisulfide modification in antibodies. Anal. Biochem. 2010, 400:89-98.
47. Tous G.I., Wei Z., Feng J., Bilbulian S., Bowen S., Smith J., Strouse R., McGeehan P., Casas-Finet J., Schenerman M.A. Characterization of a novel modification to monoclonal antibodies: Thioether cross-link of heavy and light chains. Anal. Chem. 2005, 77:2675-2682.
48. Cohen S.L., Price C., Vlasak J. β-elimination and peptide bond hydrolysis: Two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J. Am. Chem. Soc. 2007, 129:6976-6977.
49. Delta Mass http://www.abrf.org/index.cfm/dm.home.
50. Walsh G. Post-translational modifications in the context of therapeutic proteins: An introductory overview. Post-translational Modification of Protein Biopharmaceuticals 2009, 1-76. Wiley-VCH, Weinhaim. G. Walsh (Ed.).
51. Hirschberg C.B., Snider M.D. Topography of glycosylation in the rough endoplasmic reticulum and Golgi apparatus. Annu. Rev. Biochem. 1987, 56:63-87.
52. Reuter G., Gabius H.J. Eukaryotic glycosylation: Whim of nature or multipurpose tool?. Cell. Mol. Life Sci. 1999, 55:368-432.
53. Weerapana E., Imperiali B. Asparagine-linked protein glycosylation from eukaryotic to prokaryotic systems. Glycobiology 2006, 16:91-101.
54. Schellekens H. Bioequivalence and the immunogenecity of biopharmaceuticals. Nat. Rev. Drug Dis. 2002, 1:457-462.
55. Brooks S.A. Appropriate glycosylation of recombinant proteins for human use. Mol. Biotechnol. 2004, 28:241-255.
56. Mahmood I., Green M.D. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin. Pharmacokinet. 2005, 44:31-347.
57. Butler M. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems. Cytotechnology 2006, 50:57-76.
58. Morrow K.J. Advances in antibody manufacturing using mammalian cells. Biotechnol. Annu. Rev. 2007, 13:95-113.
59. Dingermann T. Recombinant therapeutic proteins: Production platforms and challenges. Biotechnol. J. 2008, 3:90-97.
60. Mukovozov I., Sabljic T., Hortelano G., Ofosu F.A. Factors that contribute to the immunogenicity of therapeytic recombinant human proteins. Throm. Haemost. 2008, 99:874-882.
61. Kawasaki N., Itoh S., Hashii N., Takakura D., Qin Y., Huang X., Yamaguchi T. The significance of glycosylation analysis in development of biopharmaceuticals. Biol. Pharm. Bull. 2009, 32:796-800.
62. Kornfeld R., Kornfeld S. Assembly of asparagines-linked oligosaccharides. Annu. Rev. Biochem. 1985, 54:631-664.
63. Shakin-Eshleman S.H., Spitalnik S.L., Kasturi L. The amino acid at the X position of an Asn-X-ser sequon is an important determinant of N-linked core-glycosylation efficiency. J. Biol. Chem. 1996, 271:6356-6363.
64. Jones J., Krag S.S., Betenbaugh M.J. Controlling N-linked glycan site occupancy. Biochim. Biophys. Acta 2005, 1726:121-137.
65. van der Steen P., Rudd P.M., Dwek R.A., Opdenakker G. Concepts and principles of O-linked glycosylation. Crit. Rev. Biochem. Mol. Biol. 1998, 33:151-208.
66. Furmanek A., Hofsteenge J. Protein C-mannosylation: Facts and questions. Acta Biochim. Pol. 2000, 47:781-789.
67. Sinclair A.M., Elliott S. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J. Pharmaceut. Sci. 2005, 94:1626-1635.
68. Bork K., Horstkorte R., Weidemann W. Increasing the sialylation of therapeutic glycoproteins: The potential of the sialic acid biosynthetic pathway. J. Pharm. Sci. 2009, 98:3499-3508.
69. Henkin J., Dudlak D., Beebe D.P., Sennello L. igh sialic acid content slows prourokinase turnover in rabbits. Throm. Res. 1991, 63:215-225.
70. Rice K.G., Lee Y.C. Oligosaccharide valency and conformation in determining binding to the asialoglycoprotein receptor hepatocytes. Advances in Enzymology and Related Areas of Molecular Biololgy 66 1993, 41-83. John Wiley & Sons Inc., New Jersey. A. Meister (Ed.).
71. Jones A.J.S., Papac D.L., Chin E.H., Keck R., Baughman S.A., Lin Y.S., Kneer J., Battersby J.E. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 2007, 17:529-540.
72. Spiro R.G. Protein glycosylation: Nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002, 12:43-56.
73. Plummer T.H.J., Elder J.H., Alexander S., Phelan A.W., Tarentino A.L. Demonstration of peptide:N-glycosidase F activity in endo-beta-N-acetylglucosaminidase F preparations. J. Biol. Chem. 1984, 259:10700-10704.
74. Tarentino A.L., Quinones G., Changhien L.-M., Plummer T.H.J. Multiple endoglycosidase F activities expressed by Flavobacterium meningosepticum endoglycosidases F2 and F3. J. Biol. Chem. 1993, 268:9702-9708.
75. Fan J.-Q., Lee Y.C. Detailed studies on substrate structure requirements of glycoamindases A and F. J. Biol. Chem. 1997, 272:27058-27064.
76. Nuck R., Zimmermann M., Sauvageot D., Josic D., Reutter W. Optimized deglycosylation of glycoproteins by peptide-N-(N-acetyl-β-glycsoaminyl)-asparagine amidase from flavobacterium meningosepticum. Glycoconjug. J. 1990, 7:279-286.
77. Edge A.S. Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: Elucidation of molecular structure and function. Biochem. J. 2003, 376:339-350.
78. Takasaki S., Mizuochi T., Kobata A. Hydrazinolysis of asparagines-linked sugar chains to produce free oligosaccharides. Methods Enzymol. 1982, 83:263-268.
79. Patel T.P., Parekh R.B. Release of oligosaccharides from glycoproteins by hydrazinolysis. Methods Enzymol. 1994, 230:57-66.
80. Kobata A. Use of endo- and exoglycosidases for structural studies of glycoconjugates. Anal. Biochem. 1979, 100:1-14.
81. Townsend R.R., Hardy M.R. Analysis of glycoprotein oligosaccharides using high-pH anion exchange chromatography. Glycobiology 1991, 1:139-147.
82. Hase S. High-performance liquid chromatography of pyridylaminated saccharides. Methods Enzymol. 1994, 230:225-237.
83. Hardy M.R., Townsend R.R. High-pH anion-exchange chromatography of glycoprotein-derived carbohydrates. Methods Enzymol. 1994, 230:208-225.
84. Anumula K.R. High-sensitivity and high-resolution methods for glycoprotein analysis. Anal. Biochem. 2000, 283:17-26.
85. Guile G.R., Rudd P.M., Wing D.R., Prime S.B., Dwek R.A. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal. Biochem. 1996, 240:210-226.
86. Evangelista R.A., Guttman A., Chen F.-T.A. Acid-catalyzed reductive amination of aldoses with 8-aminopyrene-1, 3, 6-trisufonate. Electrophoresis 1996, 17:347-351.
87. Hardy M.R., Townsend R.R., Lee Y.C. Monosaccharide analysis of glycoconjugates by anion exchange chromatography with pulsed amperometric detection. Anal. Biochem. 1988, 170:54-62.
88. Byrne B., Donohoe G.G., O'Kennedy R. Sialic acids: Carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Dis. Today 2007, 12:319-326.
89. Kelm S., Schauer R. Sialic acids in molecular and cellular interactions. Int. Rev. Cytol. 1997, 175:124-137.
90. Hara S., Yamaguchi M., Takemore Y., Sakamura M. Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human serum and urine and rat serum by reversed-phase liquid chromatography with fluorescence detection. J. Chromatogr. 1986, 377:111-119.
91. Anumula K.R. Rapid quantitative determination of sialic acids in glycoproteins by high-performance liquid chromatography with a sensitive fluorescence detection. Anal. Biochem. 1995, 230:24-30.
92. Brown M.A., Stenberg L.M. Biopharmaceuticals: Post-translational modification carboxylation and hydroxylation. Posttranslational Modifcation of Protein Biopharmaceuticals 2009, 210-252. Wiley-VCH, Weinheim. G. Walsh (Ed.).
93. Powell M.F. A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: Reactivity at Asn, Asp, Gln, and Met motifs in neutral pH solution. Formulation, Characterization, and Stability of Protein Drugs 1996, Plenum Press, New York, NY. R. Pearlman, Y.J. Wang (Eds.).
94. Clarke S., Stephenson R.C., Lowenson J.D. Lability of asparagine and aspartic acid residues in proteins and peptides: Spontaneous deamidation and isomerization reactions in stability of protein pharmaceuticals, part a. Chemical and Physical Pathways of Protein Degradation 1992, Plenum Press, New York, NY. T.J. Ahern, M.C. Manning (Eds.).
95. Brennan T.V., Clarke S. Deamidation and isoaspartate formation in model synthetic peptides: The effects of sequence and solution environment. Deamidation and Isoaspartate Formation in Peptides and Proteins 1995, 65-90. CRC Press, Washington DC. D.W. Aswad (Ed.).
96. Chazin W.J., Kossiakoff A.A. The role of secondary and tertiary structures in intramolecular deamidation of proteins. Deamidation and Isoaspartate Formation in Peptides and Proteins 1995, 193-206. CRC Press, Washington, DC. D.W. Aswad (Ed.).
97. Wearne S.J., Creighton T.E. Effect of protein conformation on rate of deamidation: Ribonuclease A. Proteins 1989, 5:8-12.
98. Robinson A.J., Rudd C.J. Deamidation of glutaminyl and asparaginyl residues in peptides and proteins. Curr. Top. Cell. Regul. 1974, 8:2247-2295.
99. Fukawa H. Changes of glutamine-peptides on heating in aqueous media. J. Chem. Soc. Jpn. 1967, 88:459-463.
100. Pearlman R., Bewley T.A. Stability and characterization of human growth hormone. Pharm. Biotechnol. 1993, 5:1-58.
101. Yokota H., Saito H., Masuoka K., Kaniwa H., Shibanuma T. Reversed phase HPLC of Met58 oxidized rhIL-11: Oxidation enhanced by plastic tubes. J. Pharm. Biomed. Anal. 2000, 24:317-324.
102. Bogosian G., Violand B.N., Dorward-King E.J., Workman W.E., Jung P.E., Kane J.F. Biosynthesis and incorporation into protein of norleucine by Escherichia coli. J. Biol. Chem. 1989, 264:531-539.
103. Muramatsu R., Misawa S., Hayashi H. Finding of an isoleucine derivative of a recombinant protein for pharmaceutical use. J. Pharm. Biomed. Anal. 2003, 31:979-987.
104. Stark G.R. Reactions of cyanate with functional groups of proteins. IV. Inertness of aliphatic hydroxyl groups. Formation of carbamyl- and acylhydantoins. Biochemistry 1965, 4:2363-2367.
105. Quan C., Alcala E., Petkoska I., Matthews D., Canova-Davis E., Taticek R., Ma S. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: Where it is, how it got there, and how it affects charge-based behavior. Anal. Biochem. 2008, 373:179-191.
106. Zhang B., Yan Y., Yuk I., Pai R., McKay P., Eigenbrot C., Dennis M., Katta V., Champion Francissen K. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal. Chem. 2008, 80:2379-2390.
107. Fischer S., Hoernschemeyer J., Mahler H.C. Glycation during storage and administration of monoclonal antibody formulations. Euro. J. Pharm. Biopharm. 2008, 70:42-50.
108. Banks D.D., Hambly D.M., Scavezze J.L., Siska C.C., Stackhouse N.L., Gadgil H.S. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J. Pharm. Sci. 2009, 98:4501-4510.
109. http://www.rcsb.org/pdb/home/home.do.
110. Philo J.S., Arakawa T. Mechanisms of protein aggregation. Curr. Pharm. Biotechnol. 2009, 10:348-351.
111. Philo J.S. A critical review of methods for size characterization of non-particulate protein aggregates. Curr. Pharm. Biotechnol. 2009, 10:359-372.
112. Arakawa T., Philo J.S., Ejima D., Tsumoto K., Arisaka F. Aggregation analysis of therapeutic proteins, Part 2. Analytical ultracentrifugation and dynamic light scattering. Bioprocess. Int. 2007, 5:36-47.
113. Berkowitz S.A. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J. 2006, 8:E590-E605.
114. Liu J., Andya J.D., Shire S.J. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J. 2006, 8:E580-E589.
115. Stafford W.F., Braswell E.H. Sedimentation velocity, multi-speed method for analyzing polydisperse solutions. Biophys. Chem. 2004, 108:273-279.
116. Philo J.S. Is any measurement method optimal for all aggregate sizes and types?. AAPS J. 2006, 8:E564-E571.
117. Arakawa T., Philo J.S., Ejima D., Sato H., Tsumoto K. Aggregation analysis of therapeutic proteins, Part 3. Principles and optimization of field-flow fractionation (FFF). Bioprocess Intern. 2007, 5:52-70.
118. Cao S., Pollastrini J., Jiang Y. Separation and characterization of protein aggregates and particles by field flow fractionation. Curr. Pharm. Biotechnol. 2009, 10:382-390.
119. Anders J.C., Parten B.F., Petrie G.E., Marlowe R.L., McEntire J.E. Using amino acid analysis to determine absorptivity constants: A validation case study using bovine serum albumin. Biopharm. Int. 2003, 16:30-37.
120. Noble J.E., Knight A.E., Reason A.J., Di Matola A., Bailey M.J.A. A Comparison of protein quantitation assays for biopharmaceutical applications. Mol. Biotechnol. 2007, 37:99-111.
121. Amino Acid Analysis Protocols 2001, Humana Press, Totowa, NJ. C. Cooper, N. Packer, K. Williams (Eds.).
122. Macchi F.D., Shen F.J., Keck R.G., Harris R.J. Amino acid analysis, using postcolumn ninhydrin detection, in a biotechnology laboratory. Methods Mol. Biol. 2001, 159:9-30. (Totowa, N. J).
123. Edelhoch H. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967, 6:1948-1954.
124. Gill S.C., Von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 1989, 182:319-326.
125. Pace C.N., Vajdos F., Fee L., Grimsley G., Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995, 4:2411-2423.
126. Traub W., Piez K.A. The chemistry and structure of collagen. Adv. Protein Chem. 1971, 25:243-352.
127. Herzberg O., Klevit R. Unraveling a bacterial hexose transport pathway. Curr. Opin. Struct. Biol. 1994, 4:814-822.
128. Olson B.J.S.C., Markwell J. Assays for the determination of protein concentration. Curr. Protoc. Protein Sci. 2007, 3.4.1-3.4.29.
129. Guideline, I.H.T. Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products. Q6b.
130. Herman A.C. Purity of biological products: Related and unrelated impurities. Dev. Biol. Stand. 1998, 16:57-62.
131. Perkins M., Theiler R., Lunte S., Jeschke M. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharmaceut. Res. 2000, 17:110-1117.
132. Harris R.J., Kabakoff B., Macchi F.D., Shen F.J., Kwong M., Andya J.D., Shire S.J., et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J. Chromatogr. B Biomed. Sci Appl. 2001, 752:233-245.
133. Beck A., Bussat M.-C., Zorn N., Robillard V., Klinguer-Hamour C., et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J. Chromatogr. B 2005, 819:203-218.
134. Ahrer K., Jungbauer A. Chromatographic and electrophoretic characterization of protein variants. J. Chromatogr. 2006, 841:110-122.
135. Berthold W., Walter J. Protein purification: Aspects of processes for pharmaceutical products. Biologicals 1994, 22:135-150.
136. Cromwell M.E.M., Hilario E., Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006, 8:E572-E579.
137. Bayol A., Bristow A., Charton E., Girard M., Jongen P. Somatropin and its variants: Structural characterization and methods of analysis. Pharmeuropa. Bio. 2004, 2004:35-45.
138. Yan B., Vallier-Douglass J., Brady L., Steen S., Han M., Pace D., et al. Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry. J. Chromatogr. 2007, 1164:153-161.
139. Xie H., Gilar M., Gebler J.C. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. Anal. Chem. 2009, 81:5699-5708.
140. Roque A.C.A., Lowe C.R., Taipa M.A. Antibodies and genetically engineered related molecules: Production and purification. Biotechnol. Prog. 2004, 20:639-654.
141. Hober S., Nord K., Linhult M. Protein A chromatography for antibody purification. J. Chromatogr. 2007, 848:40-47.
142. Low D., O'Leary R., Pujar N.S. Future of antibody purification. J. Chromatogr. 2007, 848:48-63.
143. Huse K., Bohme H.-J., Scholz G.H. Purification of antibodies by affinity chromatography. J. Biochem. Biophys. Methods 2002, 51:217-231.
144. Follman D.K., Fahrner R.L. Factorial screening of antibody purification processes using three chromatography steps without protein A. J. Chromatogr. 2004, 1024:79-85.
145. Hahn R., Schelgel R., Jungbauer A. Comparison of protein A affinity sorbents. J. Chromatogr. 2003, 790:35-51.
146. Ghose S., Hubbard B., Cramer S.M. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol. Bioeng. 2007, 96:768-779.
147. Boschetti E. Advanced sorbents for preparative protein separation purposes. J. Chromatogr. 1994, 658:207-235.
148. Gomez M.I., Lee A., Reddy B., Muir A., Soong C., Pitt A., Cheung A., Prince A. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat. Med. 2004, 10:842-848.
149. Bensinger W.I., Buckner C.D., Clift R.A., Thomas E.D. Clinical trials with staphylococcal protein A. J. Biol. Resp. Modif. 1984, 3:347-351.
150. Hoffman W.L., Ruggles A.O., Tabarya D. Chicken anti-protein A prevents Staphylococcus aureus protein A from binding to human and rabbit IgG in immunoassays and eliminates most false positive results. J. Immunol. Methods 1996, 198:67-77.
151. Carter-Franklin J.N., Victa C., McDonald P., Fahrner R. Fragments of protein A eluted during protein A affinity chromatography. J. Chromatogr. 2007, 1163:105-111.
152. Zhu-Shinomi J., Gunawan F., Thomas A., Vanderlaan M., Stults J. Trace level analysis of leached protein A in bioprocess samples without interference from the large excess of rhMAb IgG. J. Immunol. Methods 2009, 341:59-67.
153. Steindl F., Armbruster C., Hahn R., Armbruster C., Katinger H.W.D. A simple method to quantify staphylococcal protein A in the presence of human or animal IgG in various samples. J. Immunol. Methods 2000, 235:61-69.
154. Larsson A., Wejaker P.-E., Sjoquist J. Chicken anti-protein A for the detection and capturing of protein A from Staphylococcus aureus in the presence of absence of mammalian IgG. Hybridoma 1992, 11:239-243.
155. Lucas C., Nelson C., Peterson M.L., Frie S., Vetterlein D., Gregory T., Chen A.B. Enzyme-linked immunosorbent assays (ELISAs) for the determination of contaminants resulting from the immunoaffinity purification of recombinant proteins. J. Immunol. Methods 1988, 113:113-122.
156. Godfrey M.A.J., Kwasowski P., Clift R., Marks V. A sensitive enzyme-linked immunosorbent assay (ELISA) for the detection of staphylococcal protein A (SpA) present as a trace contaminant of murine immunoglobulins purified on immobilized protein A. J. Immunol. Methods 1992, 149:21-27.
157. Shukla A.A., Jiang C., Ma J., Rubacha M., Flansburg L., Lee S.S. Demonstration of robust host-cell protein clearance in biopharmaceutical downstream process. Biotechnol. Prog. 2008, 24:615-622.
158. Wang X., Hunter A.K., Mozier N.M. Host cell proteins in biologics development: Identification. Quantitation and risk assessment. Biotechnol. Bioeng. 2009, 103:446-458.
159. Eaton L.C. Host cell contaminant protein assay development for recombinant biopharmaceuticals. J. Chromatogr. 1995, 705:105-114.
160. Hoffman K. Strategies for host-cell protein analysis. Biopharm 2000, 13:38-45.
161. WHO Guideline requirements for the use of animal cells as in vitro substances for the production of biologics. Requirements for biological substances 1997, 50.
162. Flatman S., Alam I., Gerard J., Mussa N. Process analytics for purification of monoclonal antibodies. J. Chromatogr. 2007, 848:79-87.
163. Andersen K.P., Low M.A., Lie Y.S., Keller G.A., Dinowitz M. Endogenous origin of defective retroviruslike particles from a recombinant Chinese hamster ovary cell line. Virology 1991, 181:305-311.
164. Strauss D.M., Lute S., Tebaykina Z., Frey D.D., Ho C., Blank G.S., Brorson K., Chen Q., Yang B. Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol. Bioeng. 2009, 104:371-380.
165. MacGregor I.R. Screening assays for transmissible spongiform encephalopathies. Vox Sang 2004, (Suppl. 2):3-6.
166. Krutzik P.O., Nolan G.P. Intracellular phospho-protein staining techniques for flowcytometry: Monitoring single cell signaling events. Cytom. A 2003, 55:61-70.
167. Sadick M.D., Intintoli A., Quarmby V., McCoy A., Canova-Davis E., Ling V. Kinase receptor activation (KIRA): A rapid and accurate alternative to end-point bioassays. J. Pharm. Biomed. Anal. 1999, 19:883-891.
168. Brasier A.R., Fortin J.J. Nonisotopic assays for reporter gene. Curr. Protoc. Mol. Biol. 1995, 9:12-21.
169. Zhang W.-W., Labrecque S., Azoulay E., Dudley R., Matlashewski G. Development of a p53 responsive GFP reporter: Identification of live cells with p53 activity. J. Biotechnol. 2000, 79-86.
170. Zhang X., Bremer H. Control of the Escherichia coli rrnB P1 promoter strength by ppGpp. J. Biol. Chem. 1995, 270:11181-11189.
171. Fan F., Wood K.V. Bioluminescent assays for high-throughput screening. Assay Drug Dev. Technol. 2007, 5:127-136.
172. Caserman S., Menart V., Gaines Das R., Williams S., Meager A. Thermal stability of the WHO international standard of interferon alpha 2b (IFN-α2b): Application of new reporter gene assay for IFN-α2b potency determinations. J. Immunol. Methods 2007, 319:6-12.
173. Zhang J., Chen D., Gong X., Ling H., Zhang G., Wood A., Heinrich J., Cho S. Cyclic-AMP response element-based signaling assays for characterization of Trk family tyrosine kinases modulators. Neurosignals 2006, 15:26-39.
174. Gillis S., Ferm M.M., Ou W., Smith K.A. T-cell growth factor: Parameters of production and a quantitative microassay or activity. J. Immunol. Methods 1978, 120:2027.
175. Porstmann T., Ternynck T., Avrameas S. Quantitation of 5-bromo-2-deoxyuridine incorporation into DNA: An enzyme immunoassay for the assessment of the lymphoid cell proliferation response. J. Immunol. Methods 1985, 82:169-172.
176. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55.
177. Buttke T.M., McCubrey J.A., Owen T.C. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods 1993, 157:233.
178. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988, 48:4827.
179. Nakayama G.R., Caton M.C., Nova M.P., Parandoosh Z. Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J. Immunol. Methods 1997, 204:205-208.
180. Crouch S.P.M., Kozlowski R., Slater K.J., Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation that the ADP:ATP ratio may reflect mitochondrial and cytotoxicity. J. Immunol. Methods 1993, 160:81-88.
181. Pagliaro L.C., Liu B., Munker R., Andreefff M., Freireih E.J., Schneiberg D.A., Rosenblum M.G. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: An immunotoxin with anti-leukemic activity. Clin. Cancer Res. 1998, 4:1971.
182. Whiteside T.L. Measurement of cytotoxic activity of NK/LAK cells. Current Protocols in Immunology 2001.
183. Brunner K.T., Mauel J., Cerottini J.C., Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labelled allogeneic target cells in vitro: Inhibition by isoantibody and by drugs. Immunology 1968, 14:181.
184. Riedl S.J., Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 2004, 5:897-907.
185. Muppidi J., Porter M., Siegel R.M. Measurement of apoptosis and other forms of cell death. Current Protocols in Immunology 2004, 1-36. Immunology-Cell Activation.
186. Korzeniewski C., Callewaert D.M. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 1983, 64:313.
187. Malcolm A., King M.A. Detection of dead cells and measurement of cell killing by flow cytometry. J. Immunol. Methods 2000, 243:155-166.
188. Lecoeur H., de Oliveira-Pinto L.M., Gougeon M.L. Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J. Immunol. Methods 2002, 265:81-96.
189. Holmes K.L., Lantz M., Fowlkes B.J., Schmid I., Giorgi J.V. Preparation of cells and reagents for flow cytometry; Immunofluoresence and cell sorting. Current Protocols in Immunology Immunology 2001, 1-24. Immunology-Immunofluoresence and Cell Sorting.
190. Holmes K.L., Otten G., Wayne M., Yokoyama W.M. Flow cytometry analysis using the becton dickinson FACS calibur. Current Protocols in Immunology 2001, 1-22. Immunology-Immunofluorescence and Cell Sorting.
191. Golemis E.A., Adams P.D.e. Protein-Protein interactions: A Molecular Cloning Manual 2005, Cold Spring Harbor Laboratory Press, New York.
192. Lakowicz J.R. Energy transfer. Principles of Fluorescene Spectroscopy 2006, 443-475. Springer, US, (online). 3rd ed.
193. Lakowicz J.R. Time-resolved energy transfer and conformational distributions of biopolymers. Principles of Fluorescence Spectroscopy 2006, 477-506. Springer, New York, (online). 3rd ed.
194. Li Z., Gergely J., Tao T. Proximity relationships between residue 117 of rabbit skeletal troponin-I and residues in troponin-C and actin. Biophys. J. 2001, 81:321-333.
195. Selvin P.R., Rana T.M., Hearst J.E. Luminescence energy transfer. J. Am. Chem. Soc. 1994, 116:6029-6030.
196. Heyduk E., Heyduk T. Thiol-reactive, luminescent europium chelates: Luminescence probes for resonance energy transfer distance measurements in biomolecules. Anal. Biochem. 1997, 248:216-227.
197. http://www.htrf.com/technology/htrfassay/Immunoassays.
198. http://www.microcal.com/technology/itc.asp.
199. Velazquez-Campoy A., Leavitt S.A., Freire E. Characterization of protein-protein interactions by isothermal titration calorimetry. Methods in Molecular Biology: Protein-Protein Interactions. Methods and Applications 2004, 35-54. Humana Press Inc., Totowa, New Jersey. H. Fu (Ed.).
200. Sigurskjold B.W., Berland C.R., Svensson B. Thermodynamics of inhibitor binding to the catalytic site of glucoamylase from Aspergillus niger determined by displacement titration calorimetry. Biochemistry 1994, 33:10191-10199.
201. Bjelic S., Jelesarov I. A survey of the year 2007 literature on applications of isothermal titration calorimetry. J. Mol. Recognit. 2008, 21:289-311.
202. Ladbury J.E., Williams M.A. The extended interface: Measuring non-local effects in biomolecular interactions. Curr. Opin. Struct. Biol. 2004, 14:562-569.
203. Hornbeck P. Assays for antibody production. Enzyme-Linked Immunosorbent Assays. Current Protocols in Immunology Immunology 1991, 2.1.1-2.1.22. Antibodies-Enzyme-Linked Immunosorbent Assays.
204. http://www.biacore.com.
205. Sambrook J., Russell D.W. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 3rd ed.
206. Myszka D.G. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr. Opin. Biotechnol. 1999, 8:50-57.
207. Rich R.L., Papalia G.A., Flynn P.J., Furneisen J., Quinn J., Klein J.S., Katsamba P.S., Waddell M.B., Scott M., Thompson J., et al. A global benchmark study using affinity-based biosensors. Anal. Biochem. 2009, 386:194-216.
208. Rich R.L., Myszka D.G. Higher-throughput, label-free, real-time molecular interaction analysis. Anal. Biochem. 2007, 361:1-6.
209. Do T., Ho F., Heidecker B., Witte K., Chang L., Lerner L. A rapid method for determining dynamic binding capacity of resins for the purification of proteins. Protein Expr. Purif. 2008, 60:147-150.
210. Danson M., Eisenthal R. Enzyme Assays: A Practical Approach 2002, Oxford University Press, Oxford.
211. Copeland R.A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis 2000, Wiley-VCH, New York, NY.
212. Lundblad R. Using in vitro assays for therapeutic enzyme characterization. Bioprocess International December 2009, 40-44.
213. Vanderjagt D.J., Fry D.E., Glew R.H. Human glucocerebrosidase catalyses transglucosylation between glucocerebroside and retinol. Biochem. J. 1994, 300:309-315.
214. Langdell R.D., Wagner R.H., Brinkhous K.M. Effect of antihemophilic factor on one-stage clotting tests. J. Lab. Clin. Med. 1953, 41:637-647.
215. Barrowcliffe T.W., Mertens K., Preston F.E., Ingerslev J. Laboratory aspects of haemophilia therapy. Haemophilia 2002, 8:244-249.
216. Peetz D. Factor VIII methods: Which assay principle for which indication?. 36th Hemophilia Symposium Hamburg 2005 2007, 71-74. Springer Medizin Verlag, Heidelberg. I. Scharrer, W. Schramm (Eds.).